BIOLIFE SOLUTIONS INC (BLFS) Stock Fundamental Analysis
NASDAQ:BLFS - Nasdaq - US09062W2044 - Common Stock - Currency: USD
Taking everything into account, BLFS scores 4 out of 10 in our fundamental rating. BLFS was compared to 55 industry peers in the Life Sciences Tools & Services industry. No worries on liquidiy or solvency for BLFS as it has an excellent financial health rating, but there are worries on the profitability. BLFS is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year BLFS has reported negative net income.
In the past year BLFS had a positive cash flow from operations.
In the past 5 years BLFS reported 4 times negative net income.
In multiple years BLFS reported negative operating cash flow during the last 5 years.
1.2 Ratios
With a Return On Assets value of -2.63%, BLFS perfoms like the industry average, outperforming 60.00% of the companies in the same industry.
With a decent Return On Equity value of -2.95%, BLFS is doing good in the industry, outperforming 63.64% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.63% | ||
| ROE | -2.95% | ||
| ROIC | N/A |
ROA(3y)-17.53%
ROA(5y)-10.68%
ROE(3y)-21.44%
ROE(5y)-13.06%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
BLFS has a better Gross Margin (62.64%) than 89.09% of its industry peers.
In the last couple of years the Gross Margin of BLFS has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for BLFS so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 62.64% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y28.1%
GM growth 5Y-0.79%
2. Health
2.1 Basic Checks
BLFS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, BLFS has more shares outstanding
The number of shares outstanding for BLFS has been increased compared to 5 years ago.
The debt/assets ratio for BLFS has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 14.58 indicates that BLFS is not in any danger for bankruptcy at the moment.
The Altman-Z score of BLFS (14.58) is better than 98.18% of its industry peers.
BLFS has a debt to FCF ratio of 1.37. This is a very positive value and a sign of high solvency as it would only need 1.37 years to pay back of all of its debts.
With an excellent Debt to FCF ratio value of 1.37, BLFS belongs to the best of the industry, outperforming 89.09% of the companies in the same industry.
BLFS has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.01, BLFS is in the better half of the industry, outperforming 69.09% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 1.37 | ||
| Altman-Z | 14.58 |
ROIC/WACCN/A
WACC10.52%
2.3 Liquidity
BLFS has a Current Ratio of 4.73. This indicates that BLFS is financially healthy and has no problem in meeting its short term obligations.
BLFS's Current ratio of 4.73 is fine compared to the rest of the industry. BLFS outperforms 70.91% of its industry peers.
A Quick Ratio of 3.74 indicates that BLFS has no problem at all paying its short term obligations.
BLFS has a Quick ratio of 3.74. This is in the better half of the industry: BLFS outperforms 67.27% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.73 | ||
| Quick Ratio | 3.74 |
3. Growth
3.1 Past
BLFS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 72.64%, which is quite impressive.
Looking at the last year, BLFS shows a very negative growth in Revenue. The Revenue has decreased by -28.79% in the last year.
BLFS shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 24.59% yearly.
EPS 1Y (TTM)72.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%95.65%
Revenue 1Y (TTM)-28.79%
Revenue growth 3Y-11.63%
Revenue growth 5Y24.59%
Sales Q2Q%-24.54%
3.2 Future
BLFS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 44.23% yearly.
BLFS is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 16.22% yearly.
EPS Next Y80.67%
EPS Next 2Y46.42%
EPS Next 3Y44.23%
EPS Next 5YN/A
Revenue Next Year-8.73%
Revenue Next 2Y3.59%
Revenue Next 3Y10.13%
Revenue Next 5Y16.22%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for BLFS. In the last year negative earnings were reported.
BLFS is valuated quite expensively with a Price/Forward Earnings ratio of 298.88.
The rest of the industry has a similar Price/Forward Earnings ratio as BLFS.
The average S&P500 Price/Forward Earnings ratio is at 21.76. BLFS is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 298.88 |
4.2 Price Multiples
BLFS's Enterprise Value to EBITDA ratio is in line with the industry average.
The rest of the industry has a similar Price/Free Cash Flow ratio as BLFS.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 110.67 | ||
| EV/EBITDA | 274.59 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates BLFS does not grow enough to justify the current Price/Earnings ratio.
A more expensive valuation may be justified as BLFS's earnings are expected to grow with 44.23% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y46.42%
EPS Next 3Y44.23%
5. Dividend
5.1 Amount
BLFS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
21.95
-0.77 (-3.39%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners102.55%
Inst Owner Change0%
Ins Owners2.84%
Ins Owner Change2.67%
Market Cap1.04B
Analysts82.67
Price Target31.85 (45.1%)
Short Float %9.43%
Short Ratio7.21
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)288.97%
Min EPS beat(2)81.45%
Max EPS beat(2)496.49%
EPS beat(4)3
Avg EPS beat(4)96.58%
Min EPS beat(4)-246.6%
Max EPS beat(4)496.49%
EPS beat(8)6
Avg EPS beat(8)53.57%
EPS beat(12)7
Avg EPS beat(12)-13.03%
EPS beat(16)9
Avg EPS beat(16)-13.48%
Revenue beat(2)2
Avg Revenue beat(2)4.48%
Min Revenue beat(2)3.34%
Max Revenue beat(2)5.63%
Revenue beat(4)4
Avg Revenue beat(4)10.58%
Min Revenue beat(4)3.34%
Max Revenue beat(4)17.36%
Revenue beat(8)5
Avg Revenue beat(8)5.66%
Revenue beat(12)7
Avg Revenue beat(12)2.33%
Revenue beat(16)10
Avg Revenue beat(16)2.43%
PT rev (1m)-0.35%
PT rev (3m)-0.35%
EPS NQ rev (1m)0%
EPS NQ rev (3m)12.69%
EPS NY rev (1m)-5.45%
EPS NY rev (3m)16.66%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.21%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.65%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 298.88 | ||
| P/S | 11.08 | ||
| P/FCF | 110.67 | ||
| P/OCF | 71.34 | ||
| P/B | 2.96 | ||
| P/tB | 7.94 | ||
| EV/EBITDA | 274.59 |
EPS(TTM)-0.29
EYN/A
EPS(NY)0.07
Fwd EY0.33%
FCF(TTM)0.2
FCFY0.9%
OCF(TTM)0.31
OCFY1.4%
SpS1.98
BVpS7.41
TBVpS2.76
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.63% | ||
| ROE | -2.95% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 62.64% | ||
| FCFM | 10.01% |
ROA(3y)-17.53%
ROA(5y)-10.68%
ROE(3y)-21.44%
ROE(5y)-13.06%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y28.1%
GM growth 5Y-0.79%
F-Score6
Asset Turnover0.24
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 1.37 | ||
| Debt/EBITDA | 0.7 | ||
| Cap/Depr | 66.95% | ||
| Cap/Sales | 5.52% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 408.63% | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.73 | ||
| Quick Ratio | 3.74 | ||
| Altman-Z | 14.58 |
F-Score6
WACC10.52%
ROIC/WACCN/A
Cap/Depr(3y)80.15%
Cap/Depr(5y)101.86%
Cap/Sales(3y)10.07%
Cap/Sales(5y)11.77%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)72.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%95.65%
EPS Next Y80.67%
EPS Next 2Y46.42%
EPS Next 3Y44.23%
EPS Next 5YN/A
Revenue 1Y (TTM)-28.79%
Revenue growth 3Y-11.63%
Revenue growth 5Y24.59%
Sales Q2Q%-24.54%
Revenue Next Year-8.73%
Revenue Next 2Y3.59%
Revenue Next 3Y10.13%
Revenue Next 5Y16.22%
EBIT growth 1Y90.88%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year295.82%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y149.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y546.13%
OCF growth 3YN/A
OCF growth 5Y47.44%